Effect of Lianhuaqingwen Capsules on Airway Inflammation in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Table 4
Levels of IL-8, TNF-, IL-17, and IL-23 in the blood of the LHQW group, the conventional group, and subgroups before and after treatment.
Total
High-risk subgroups
Low-risk subgroups
LHQW group ()
Conventional group ()
LHQW group ()
Conventional group ()
LHQW group ()
Conventional group ()
IL-8
Before treatment (mean ± SD, pg/mL)
After treatment (mean ± SD, pg/mL)
value
0.021
0.125
0.145
0.448
0.049
0.098
TNF-
Before treatment (mean ± SD, pg/mL)
After treatment (mean ± SD, pg/mL)
value
0.238
0.263
0.551
0.244
0.291
0.739
IL-17
Before treatment (mean ± SD, pg/mL)
After treatment (mean ± SD, pg/mL)
value
0.004
0.232
0.041
0.354
0.047
0.450
IL-23
Before treatment (mean ± SD, pg/mL)
After treatment (mean ± SD, pg/mL)
value
0.208
0.303
0.617
0.563
0.169
0.335
SD: standard deviation, compared with values before treatment, compared with values before treatment (lower values indicated greater improvement in the expression of inflammatory mediators).